Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the
personal and economic burden of obesity-related complications becomes ever more …

Metformin is a biguanide that is used as first-line treatment of type 2 diabetes mellitus and is
effective as monotherapy and in combination with other glucose-lowering medications. It is …

Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the
US Food and Drug Administration for chronic weight management. This paper reviews data …

Type 2 diabetes mellitus is a growing global public health problem, the prevalence of which
is projected to increase in the succeeding decades. It is potentially associated with many …

Chronic wounds are a common complication in patients with diabetes that often lead to
amputation. These non-healing wounds are described as being stuck in a persistent …

Patients with type 2 diabetes mellitus often require multifactorial pharmacological treatment
due to different comorbidities. An increasing number of concomitantly taken medications …

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering
hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class …

Purpose Obesity is associated with alterations in appetite, gastrointestinal hormone levels
and excessive fat mass. We previously published a double-blind, placebo-controlled …

Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …

The prevalence of type 2 diabetes is expected to increase gradually with the prolongation of
population aging and life expectancy. In addition to macrovascular and microvascular …